It arriving in Europe VeriSeq, a noninvasive prenatal screening test next generation. The technology allows you to run in quickly and accurately testing, saving both time and money. At the base is the next-generation sequencing or NGS, integrated with a software analysis and preparation of libraries for in vitro diagnostic devices. The result is an automated solution that allows you to detect fetal chromosomal abnormalities more common in one day.
For VeriSeq solution just a sample of maternal blood from the tenth week of pregnancy. From here the test detects fetal cells and to analyze the DNA. In this way it is possible to detect trisomy 21, trisomy 18 and trisomy 13. These types of anomalies are at the base respectively of Down syndrome, Edwards syndrome and Patau syndrome. The test also can detect some diseases related to sex chromosomes, with a very low rate of false positives and false negatives. Thanks to the procedure, it is thus possible to minimize the use of invasive prenatal testing.
What is so new VeriSeq compared to traditional invasive prenatal screening test does not? Leverage sequencing coupled readings, using the chemical synthesis developed by Illumina. To this it adds important innovations in terms not only of tools and software, but also workflow. The result is greater accessibility to this kind of test, even by smaller laboratories. The greater efficiency of the process also allows to analyze more than 90 samples in one day. In this way, the process is more rapid.
The manufacturer has evaluated the clinical precision of tests on more than 3,100 maternal blood samples. VeriSeq has proved a highly reliable solution, as well as rapid. Parents who rely on partner laboratories Illumina can therefore rest assured that they will have the results of which are in need of a few days, with the security of a reliable answer to their doubts.